Cian Healthcare Ltd
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]
- Market Cap ₹ 12.5 Cr.
- Current Price ₹ 5.01
- High / Low ₹ 7.66 / 2.99
- Stock P/E
- Book Value ₹ 13.0
- Dividend Yield 0.00 %
- ROCE -10.6 %
- ROE -30.3 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.39 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -11.6% over past five years.
- Promoter holding is low: 27.1%
- Company has a low return on equity of -6.85% over last 3 years.
- Company might be capitalizing the interest cost
- Promoters have pledged 34.5% of their holding.
- Company has high debtors of 206 days.
- Promoter holding has decreased over last 3 years: -39.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 57 | 74 | 78 | 69 | 62 | 31 | |
| 50 | 62 | 74 | 56 | 51 | 37 | |
| Operating Profit | 7 | 12 | 4 | 13 | 11 | -7 |
| OPM % | 13% | 16% | 6% | 19% | 18% | -21% |
| 1 | 0 | 0 | 1 | 0 | -12 | |
| Interest | 7 | 8 | 7 | 6 | 6 | 3 |
| Depreciation | 4 | 3 | 4 | 5 | 5 | 4 |
| Profit before tax | -4 | 1 | -6 | 2 | 0 | -26 |
| Tax % | 7% | 91% | -8% | -2% | -1,600% | -0% |
| -4 | 0 | -6 | 2 | 1 | -26 | |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.34 | -10.39 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -12% |
| 3 Years: | -27% |
| TTM: | -50% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1716% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -15% |
| 3 Years: | -37% |
| 1 Year: | 62% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -7% |
| Last Year: | -30% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 25 | 25 | 25 | 25 |
| Reserves | 35 | 35 | 30 | 32 | 33 | 7 |
| 73 | 71 | 63 | 61 | 56 | 55 | |
| 25 | 28 | 47 | 42 | 47 | 69 | |
| Total Liabilities | 157 | 157 | 166 | 160 | 161 | 156 |
| 39 | 37 | 50 | 45 | 39 | 35 | |
| CWIP | 25 | 26 | 13 | 14 | 15 | 15 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 |
| 87 | 90 | 98 | 97 | 102 | 101 | |
| Total Assets | 157 | 157 | 166 | 160 | 161 | 156 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| -7 | 6 | 9 | 5 | 12 | 21 | |
| -27 | 3 | 1 | 3 | -1 | -0 | |
| 36 | -10 | -11 | -7 | -10 | -4 | |
| Net Cash Flow | 1 | -1 | -1 | -0 | -0 | 17 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 128 | 94 | 125 | 140 | 121 | 206 |
| Inventory Days | 267 | 313 | 300 | 400 | 486 | 420 |
| Days Payable | 220 | 209 | 270 | 296 | 371 | 671 |
| Cash Conversion Cycle | 175 | 197 | 155 | 244 | 236 | -45 |
| Working Capital Days | 15 | 16 | 38 | 41 | 26 | -729 |
| ROCE % | 7% | 0% | 7% | 5% | -11% |
Documents
Announcements
-
Board Meeting Outcome for Outcome For The Meeting (CIAN/RPIC/2025-26/06) Of The Resolution Plan Implementation Committee Held On February 01, 2026, By The Company.
5h - NCLT-approved resolution implemented; ₹37,30,13,553 received; RPIC dissolved; audited consolidated results approved; auditor disclaimer.
-
Board Meeting Outcome for Outcome Of The Meeting (CIAN/RPIC/2025-26/04) Of The Resolution Plan Implementation Committee ("Implementation Committee") Held On Friday, January 23, 2026, By The Company.
23 Jan - NCLT-approved plan: 67,74,897 promoter shares cancelled; public 1,82,20,867 reduced and 12,50,000 fresh allotted (Jan 23, 2026).
-
Board Meeting Intimation for Prior Intimation Regarding The Resolution Plan Implementation Committee (CIAN/RPIC/2025-26/04) Meeting Scheduled To Be Held On January 23, 2026.
19 Jan - RPIC meeting Jan 23 to approve promoters' share extinguishment to zero and fresh share allotments (record date Jan 21, 2026).
-
Board Meeting Intimation for Prior Intimation Regarding The Resolution Plan Implementation Committee (CIAN/RPIC/2025-26/04) Meeting Scheduled To Be Held On January 23, 2026.
19 Jan - Jan 23 meeting to extinguish promoters' shareholding to zero; public shareholders allotted fresh shares (record date Jan 21, 2026).
-
Board Meeting Outcome for Board Meeting Outcome For The Meeting (CIAN/RPIC/2025-26/03) Of The Resolution Plan Implementation Committee Held On January 14, 2026, By The Company.
14 Jan - NCLT approved resolution plan (Dec 18, 2025); unaudited H1 Sep 30, 2025 results, auditor disclaimer, RP Roshen Chordiya.
Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.